The Biotech Growth Trust (LON:BIOG) Stock Crosses Below 200-Day Moving Average – Should You Sell?

The Biotech Growth Trust PLC (LON:BIOG) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 958.04 ($12.06) and traded as low as GBX 850.45 ($10.70). The Biotech Growth Trust shares last traded at GBX 852 ($10.72), with a volume of 48,347 shares.

The Biotech Growth Trust Trading Down 0.4 %

The company has a market cap of £243.41 million, a price-to-earnings ratio of 2.86 and a beta of 0.50. The firm has a 50-day moving average price of GBX 869.02 and a 200 day moving average price of GBX 957.50. The company has a current ratio of 0.59, a quick ratio of 0.00 and a debt-to-equity ratio of 11.02.

The Biotech Growth Trust (LON:BIOG) last released its quarterly earnings data on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) earnings per share (EPS) for the quarter. The Biotech Growth Trust had a return on equity of 26.96% and a net margin of 95.33%.

Insider Activity at The Biotech Growth Trust

In other The Biotech Growth Trust news, insider Julie Tankard purchased 1,022 shares of The Biotech Growth Trust stock in a transaction on Wednesday, December 4th. The stock was bought at an average price of GBX 972 ($12.23) per share, for a total transaction of £9,933.84 ($12,503.26). Also, insider Nicola Shepherd purchased 1,000 shares of The Biotech Growth Trust stock in a transaction on Monday, January 13th. The shares were acquired at an average price of GBX 846 ($10.65) per share, with a total value of £8,460 ($10,648.21). Insiders purchased 6,222 shares of company stock worth $5,659,584 in the last 90 days. 0.71% of the stock is currently owned by company insiders.

The Biotech Growth Trust Company Profile

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).